Atlas Trials

Grifols Therapeutics LLC

46 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Grifols Therapeutics LLC

RecordFirmDate
A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) (NCT07555483)Grifols Therapeutics LLC2026-05-05
A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (NCT07540221)Grifols Therapeutics LLC2026-04-02
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma (NCT05645107)Grifols Therapeutics LLC2022-12-26
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency (NCT04722887)Grifols Therapeutics LLC2021-08-13
A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients (NCT04847141)Grifols Therapeutics LLC2021-04-28
Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19) (NCT04547140)Grifols Therapeutics LLC2021-01-29
A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency (NCT04566692)Grifols Therapeutics LLC2020-11-24
Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19) (NCT04480424)Grifols Therapeutics LLC2020-09-17
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency (NCT04561115)Grifols Therapeutics LLC2020-09-02
Study Evaluating IGSC 20% Flexible Dosing in Treatment-Experienced and Treatment-Naive Subjects With Primary Immunodeficiency (NCT03814798)Grifols Therapeutics LLC2019-12-01
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites (NCT03451292)Grifols Therapeutics LLC2018-07-24
Alphanate in Immune Tolerance Induction Therapy (NCT03095287)Grifols Therapeutics LLC2018-01-03
Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human) (NCT03351933)Grifols Therapeutics LLC2017-10-31

Track Grifols Therapeutics LLC automatically

Every clearance here is in the API, with alerts when new ones post.